$4.42
Insights on Adaptive Biotechnologies Corp
Revenue is down for the last 2 quarters, 48.92M → 37.91M (in $), with an average decrease of 22.5% per quarter
Netprofit is down for the last 2 quarters, -47.81M → -50.3M (in $), with an average decrease of 5.2% per quarter
In the last 1 year, Seagen, Inc. has given 83.0% return, outperforming this stock by 126.6%
In the last 3 years, Novo Nordisk A/s has given 20.4% return, outperforming this stock by 111.1%
0.45%
Downside
Day's Volatility :6.58%
Upside
6.16%
40.95%
Downside
52 Weeks Volatility :75.81%
Upside
59.04%
Period | Adaptive Biotechnologies Corp | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -32.72% | 0.3% | 0.0% |
6 Months | -42.6% | 1.7% | 0.0% |
1 Year | -43.55% | -4.0% | -2.4% |
3 Years | -91.71% | 17.2% | -6.5% |
Market Capitalization | 691.3M |
Book Value | $2.5 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -1.36 |
PEG Ratio | 0.0 |
Wall Street Target Price | 9.17 |
Profit Margin | -109.04% |
Operating Margin TTM | -134.38% |
Return On Assets TTM | -15.1% |
Return On Equity TTM | -46.15% |
Revenue TTM | 179.7M |
Revenue Per Share TTM | 1.25 |
Quarterly Revenue Growth YOY | -20.7% |
Gross Profit TTM | -13.7M |
EBITDA | -171.4M |
Diluted Eps TTM | -1.36 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.38 |
EPS Estimate Next Year | -1.15 |
EPS Estimate Current Quarter | -0.34 |
EPS Estimate Next Quarter | -0.15 |
What analysts predicted
Upside of 107.47%
FY17 | Y/Y Change | |
---|---|---|
Revenue | 38.4M | - |
Net Income | -42.8M | - |
Net Profit Margin | -111.4% | - |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 55.7M | ↑ 44.77% |
Net Income | -46.4M | ↑ 8.44% |
Net Profit Margin | -83.44% | ↑ 27.96% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 85.1M | ↑ 52.83% |
Net Income | -58.8M | ↑ 26.64% |
Net Profit Margin | -69.14% | ↑ 14.3% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 98.4M | ↑ 15.65% |
Net Income | -139.6M | ↑ 137.39% |
Net Profit Margin | -141.93% | ↓ 72.79% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 154.3M | ↑ 56.88% |
Net Income | -205.6M | ↑ 47.25% |
Net Profit Margin | -133.22% | ↑ 8.71% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 185.3M | ↑ 20.06% |
Net Income | -142.5M | ↓ 30.71% |
Net Profit Margin | -76.88% | ↑ 56.34% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 43.7M | ↑ 13.05% |
Net Income | -51.6M | ↓ 17.43% |
Net Profit Margin | -118.25% | ↑ 43.65% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 47.8M | ↑ 9.55% |
Net Income | -45.2M | ↓ 12.51% |
Net Profit Margin | -94.44% | ↑ 23.81% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 55.2M | ↑ 15.4% |
Net Income | -24.5M | ↓ 45.71% |
Net Profit Margin | -44.43% | ↑ 50.01% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 37.6M | ↓ 31.8% |
Net Income | -61.7M | ↑ 151.76% |
Net Profit Margin | -163.99% | ↓ 119.56% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 48.9M | ↑ 29.96% |
Net Income | -47.8M | ↓ 22.56% |
Net Profit Margin | -97.72% | ↑ 66.27% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 37.9M | ↓ 22.5% |
Net Income | -50.3M | ↑ 5.21% |
Net Profit Margin | -132.65% | ↓ 34.93% |
FY17 | Y/Y Change | |
---|---|---|
Total Assets | 362.5M | - |
Total Liabilities | 587.1M | - |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 332.7M | ↓ 8.22% |
Total Liabilities | 590.8M | ↑ 0.63% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 912.3M | ↑ 174.22% |
Total Liabilities | 341.3M | ↓ 42.24% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 1.1B | ↑ 22.37% |
Total Liabilities | 373.1M | ↑ 9.34% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 923.3M | ↓ 17.29% |
Total Liabilities | 319.2M | ↓ 14.45% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 856.6M | ↓ 7.23% |
Total Liabilities | 392.5M | ↑ 22.95% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 806.6M | ↓ 6.01% |
Total Liabilities | 288.3M | ↓ 5.45% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 884.2M | ↑ 9.62% |
Total Liabilities | 396.4M | ↑ 37.49% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 856.6M | ↓ 3.12% |
Total Liabilities | 392.5M | ↓ 0.98% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 791.5M | ↓ 7.61% |
Total Liabilities | 367.5M | ↓ 6.37% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 764.5M | ↓ 3.4% |
Total Liabilities | 368.6M | ↑ 0.29% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 717.7M | ↓ 6.13% |
Total Liabilities | 356.0M | ↓ 3.4% |
FY17 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -34.9M | - |
Investing Cash Flow | 36.4M | - |
Financing Cash Flow | 50.0M | - |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -32.3M | ↓ 7.46% |
Investing Cash Flow | 736.0K | ↓ 97.98% |
Financing Cash Flow | 1.2M | ↓ 97.51% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 205.4M | ↓ 736.73% |
Investing Cash Flow | -481.7M | ↓ 65547.96% |
Financing Cash Flow | 319.9M | ↑ 25534.29% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -149.7M | ↓ 172.87% |
Investing Cash Flow | -117.0M | ↓ 75.7% |
Financing Cash Flow | 293.6M | ↓ 8.23% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -192.7M | ↑ 28.76% |
Investing Cash Flow | 181.2M | ↓ 254.82% |
Financing Cash Flow | 27.1M | ↓ 90.75% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -183.9M | ↓ 4.56% |
Investing Cash Flow | 2.9M | ↓ 98.4% |
Financing Cash Flow | 132.3M | ↑ 387.24% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -47.1M | ↓ 26.98% |
Investing Cash Flow | 4.7M | ↓ 87.41% |
Financing Cash Flow | 4.0M | ↑ 45.14% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -42.4M | ↓ 9.89% |
Investing Cash Flow | 58.0M | ↑ 1122.4% |
Financing Cash Flow | 125.5M | ↑ 3045.86% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -30.0M | ↓ 29.21% |
Investing Cash Flow | -97.5M | ↓ 268.14% |
Financing Cash Flow | 6.0K | ↓ 100.0% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -59.2M | ↑ 97.05% |
Investing Cash Flow | 63.0M | ↓ 164.56% |
Financing Cash Flow | 672.0K | ↑ 11100.0% |
Sell
Neutral
Buy
Adaptive Biotechnologies Corp is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Adaptive Biotechnologies Corp | -7.92% | -42.6% | -43.55% | -91.71% | -89.03% |
![]() Moderna, Inc. | 8.62% | -38.31% | -54.89% | -50.93% | 320.86% |
![]() Regeneron Pharmaceuticals, Inc. | -1.38% | 9.73% | 9.82% | 65.7% | 115.07% |
![]() Novo Nordisk A/s | -1.43% | 23.95% | 58.41% | 192.13% | 336.59% |
![]() Seagen, Inc. | 0.74% | 10.42% | 83.05% | 20.41% | 247.89% |
![]() Vertex Pharmaceuticals Incorporated | -8.19% | 7.19% | 13.58% | 55.97% | 97.18% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Adaptive Biotechnologies Corp | NA | NA | 0.0 | -1.38 | -0.46 | -0.15 | 0.0 | 2.5 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -12.72 | -0.22 | -0.07 | 0.0 | 35.32 |
![]() Regeneron Pharmaceuticals, Inc. | 23.18 | 23.18 | 1.75 | 42.5 | 0.17 | 0.09 | 0.01 | 234.47 |
![]() Novo Nordisk A/s | 41.18 | 41.18 | 4.02 | 2.67 | 0.89 | 0.22 | 0.01 | 20.77 |
![]() Seagen, Inc. | NA | NA | 18.53 | -4.16 | -0.28 | -0.13 | 0.03 | 13.52 |
![]() Vertex Pharmaceuticals Incorporated | 26.38 | 26.38 | 0.5 | 15.04 | 0.23 | 0.14 | 0.0 | 64.05 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Adaptive Biotechnologies Corp | Buy | $691.3M | -89.03% | NA | -109.04% |
![]() Moderna, Inc. | Buy | $30.4B | 320.86% | 24.73 | -38.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $88.5B | 115.07% | 23.18 | 30.47% |
![]() Novo Nordisk A/s | Buy | $459.0B | 336.59% | 41.18 | 35.11% |
![]() Seagen, Inc. | Hold | $40.2B | 247.89% | NA | -32.61% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $90.5B | 97.18% | 26.38 | 35.94% |
Viking Global Investors LP
Vanguard Group Inc
Matrix Capital Management Company, LLC
ARK Investment Management LLC
BlackRock Inc
Sumitomo Mitsui Trust Holdings Inc
Adaptive Biotechnologies Corp’s price-to-earnings ratio stands at None
Read Morewe are a commercial-stage, biotechnology organization located in the hot biotech locations of seattle, washington and south san francisco, ca. our world class scientists have invented a patent-pending technology that combines advances in high-throughput sequencing with state-of-the-art computer infrastructure to provide an in-depth analysis of the t- and b-cell repertoire, a specific and important part of the immune system. this information is driving the r&d community to support the fights against cancer, auto-immune disease, and much, much more. we're often asked to describe our company culture. it is very easy ... we're a hard working group of top-notch individuals who are passionate about wanting to make a difference in the world. we know our employees are our most valuable asset, and every employee’s contribution is appreciated. open communication and collaboration are always encouraged in every interaction throughout the organization. we have high expectations of ourselves, and
Organization | Adaptive Biotechnologies Corp |
Employees | 790 |
CEO | Mr. Chad M. Robins M.B.A, M.B.A. |
Industry | Commercial Services |
Asymmetric Smart Alpha S&p 500 Etf
$4.42
-7.14%
Advisorshares Alpha Dna Equity Sentiment Etf
$4.42
-7.14%
Falcon's Beyond Global Inc
$4.42
-7.14%
Jaguar Global Growth Corporation I
$4.42
-7.14%
Missfresh Ltd
$4.42
-7.14%
Shuaa Partners Acquisition Corp I
$4.42
-7.14%
Rose Hill Acquisition Corp
$4.42
-7.14%
Partners Bancorp
$4.42
-7.14%
Mercantile Bank Corp
$4.42
-7.14%